Australian Team Finds Blood miRNA with Potential for Early Diagnosis of Malignant Mesothelioma | GenomeWeb

Blood levels of the microRNA miR-625-3p could serve as a predictive biomarker for the early diagnosis of malignant pleural mesothelioma, according to research by a group from the Concord Hospital Asbestos Diseases Research Institute in Sydney, Australia.

The team reported its findings from a small discovery and validation study of miRNAs in blood plasma in a presentation at the third European Lung Cancer Conference last month. The researchers also plan to publish a fuller account of the study in an upcoming issue of the Journal of Thoracic Oncology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.